Prolongation of Survival Time of Mice Inoculated with Myeloid Leukemia Cells by Inducers of Normal Differentiation

Yoshio Honma, Takashi Kasukabe, Junko Okabe, and Motoo Hozumi

Department of Chemotherapy, Saitama Cancer Center Research Institute, Ina-machi, Kitasagicho-gun, Saitama-362, Japan

ABSTRACT

Studies were made on the effects of inducers on the leukemogenicity of sensitive mouse myeloid leukemia cells (M1) that could be induced to undergo cell differentiation into mature granulocytes and macrophages in vitro by incubation with inducers (certain proteins, bacterial lipopolysaccharides, or glucocorticoids) and of resistant M1 cells that could not be induced to differentiate into mature cells. Inducers of cell differentiation significantly enhanced the survival times of mice inoculated with sensitive cells but scarcely affected the survival times of mice inoculated with resistant cells. Some mice inoculated with the sensitive cells and treated with lipopolysaccharide did not develop leukemia. The sensitive and resistant clone cells contained similar common tumor-related surface antigens. Treatment with lipopolysaccharide was also effective in athymic nude mice inoculated with the sensitive M1 cells. Lipopolysaccharide or glucocorticoid significantly stimulated differentiation of the sensitive cells cultured in a diffusion chamber in vivo but had little effect on differentiation of resistant cells. These results suggest the possibility of treating, with partial success, leukemia in vivo with differentiation inducers.

INTRODUCTION

Treatment with various inducers in vitro causes mouse myeloid leukemia (M1) cells to differentiate into forms that are functionally and morphologically similar to macrophages and granulocytes (14, 16, 27). Syngeneic mice inoculated with untreated M1 cells all died of leukemia, but on treatment with an inducer in vitro the M1 cells lost their leukemogenicity (17). We previously showed that resistant M1 cells that could not be induced to differentiate into mature cells were much more leukemogenic than were sensitive cells that could be induced to undergo cell differentiation (11). These findings, which suggest that leukemogenicity of M1 cells in syngeneic mice is related to in vivo inducibility of differentiation of the cells, may have significant implications for leukemia therapy.

The present experiments were undertaken to clarify 3 questions. (a) Is the leukemogenicity of sensitive cells affected by treatment with inducers of cell differentiation? (b) Do resistant and sensitive cells differ in immunogenicity? (c) Can the possible decrease of leukemogenicity caused by inducers be separated from enhancement of T-lymphocyte-mediated immune responses?

MATERIALS AND METHODS

Animals. Inbred SL mice were maintained as reported previously (11). Athymic nude mice with a BALB/c genetic background were supplied by CLEA Japan Inc., Tokyo, Japan, and housed under specific-pathogen-free conditions using Clean Racks (Sanki Kogyo, Tokyo, Japan). Five-week-old female mice were used for experiments.

Cells and Cell Culture. The cells used were 3 clones of the M1 cell line isolated from a spontaneous myeloid leukemia in an SL mouse (13). The cells were cultured in suspension in 6-cm Falcon plastic dishes in Eagle’s minimum essential medium with twice the normal concentrations of amino acids and vitamins and supplemented with 10% heat-inactivated calf serum. The cells were cultured at 37° in a humid atmosphere at 5% CO2 in air.

Administration of LPS and Dexamethasone. Preparations of LPS (Boivin type) from Salmonella typhimurium, Salmonella abortus-equi, and Escherichia coli O26:B6 were obtained from Difco Laboratories, Detroit, Mich. LPS was dissolved in sterilized PBS, and 0.2 ml of the solution was injected i.p. into mice twice a week. Dexamethasone was purchased from Sigma Chemical Co., St. Louis, Mo. Stock steroid solution (20 mg/ml) was prepared in absolute ethanol. Mice were given i.p injections of 0.2 ml of PBS containing 1 μl of the steroid solution (20 μg/mouse) 3 times a week. The first dose of LPS or dexamethasone was injected 3 hr after tumor challenge.

Test of Phagocytosis. Phagocytic activity was assayed as reported previously (10). Cells were inoculated at a concentration of 4 to 5 × 10^6 cells/ml into 2 ml of culture medium and incubated with 0.1 ml of LPS solution diluted with PBS. After 48 hr, the cells were washed and incubated for 4 hr with a suspension of polystyrene latex particles (2 μl/ml of serum-free culture medium). Then the cells were washed thoroughly 4 times with PBS, and the percentage of phagocytic cells was calculated.

Culture and Morphological Examination of Cells in Diffusion Chambers. The chambers were made as described previously (11), and 0.1 ml of cell suspension (5 × 10^6 cells) was placed in each. Two chambers were implanted into the peritoneal cavity of each mouse. The cells were collected by the Ficoll-pronase method for chamber processing (2). Cell types were determined from their morphology after staining with May-Grunwald-Giemsa.

Antiserum. M1 cells were incubated with mitomycin C, 25 μg/ml, at 37° for 30 min. Then they were washed 3 times with PBS and resuspended in PBS to give 5 × 10^7 cells/ml. Syngeneic SL mice were given s.c. injections of 0.2 ml of cell
cells in the diffusion chambers were myeloblastic in LPS; their differentiation was significantly enhanced; only 5% of the sensitive (D54) cells. DR3 cells; b, DS1-1 cells; c, DS4 cells.

Phagocytosis was determined 2 days after seeding the cells with LPS from injections of LPS. Mice were given i.p. injections of 10^2 cells. Mice treated with 10^2 cells in an intermediate stage of differentiation in the diffusion chambers. Morphological differentiation of the sensitive M1 cells in intermediate stages of differentiation in the diffusion chambers. These results indicate that injection of an inducer of differentiation of M1 cells in vitro can also enhance differentiation of the cells in vivo.

**Immune Adherence Test.** Cells were washed 3 times with special gelatin-Veronal buffer, consisting of 137 mM NaCl, 5.7 mM KCl, 0.15 mM CaCl_2, 0.5 mM MgCl_2, 3.1 mM Veronal (5.5-diethylbarbituric acid), 1.8 mM sodium Veronal, 5.6 mM glucose, and 0.1% gelatin, pH 7.5. Guinea pig serum was absorbed 3 times with packed M1 cells as described previously (29) and was used as the complement preparation. The immune adherence test was carried out on washed cells as described by Nishioka et al. (23). The percentage of cells with rosettes was calculated.

**Statistical Analysis.** The results were evaluated by an unpaired 2-tailed t test and were considered significant if the p value was less than 5%.

**RESULTS**

**Enhancement of Differentiation of M1 Cells in Vivo by LPS or Glucocorticoid.** The differentiation-stimulating activities of mouse serum on normal mouse bone marrow cells and M1 cells were enhanced by injection with LPS, and LPS itself induced differentiation of M1 cells (6, 9, 19, 21, 31). The effects of LPS from *S. typhimurium* on induction of phagocytic activity, a typical marker of differentiated cells, in DR3, DS1-1, and DS4 clone cells are shown in Chart 1. After treatment of the cells with LPS, 0.25 μg/ml, for 2 days, about 45% of the sensitive DS4 cells were phagocytic, whereas only 7% of the less sensitive DS1-1 cells were phagocytic. None of the resistant DR3 cells were phagocytic, even after treatment with LPS, 10 μg/ml.

We have found that, in diffusion chambers in syngeneic SL mice without any additional manipulation or injection of inducer, resistant M1 cells remained undifferentiated, whereas sensitive M1 cells differentiated into mature granulocytes and macrophages (11). Therefore, we injected LPS i.p. into syngeneic SL mice to determine whether it would enhance differentiation of sensitive cells in the diffusion chambers. As shown in Chart 2, their differentiation was significantly enhanced; only 5% of the cells in the diffusion chambers were myeloblastic in LPS-treated mice, whereas 55% were myeloblastic in the controls. LPS treatment also slightly increased the numbers of resistant M1 cells in intermediate stages of differentiation in the diffusion chambers. Morphological differentiation of the sensitive M1 cells, but not the resistant ones, was also markedly enhanced by injection of dexamethasone. These results indicate that

**Prolongation of Survival Times of Mice Inoculated with M1 Cells by LPS Treatment.** The effects of LPS on the survival times of mice inoculated with these cell clones were examined. For this, syngeneic mice inoculated with 10^5 cells of these clones were given injections of 25 μg of LPS from *S. typhimurium* twice a week. The first dose was injected 3 hr after tumor challenge. As expected, LPS significantly increased the survival times of mice given the sensitive M1 cells, but not that of the mice given the resistant cells (Chart 3). The mean survival time of untreated mice inoculated with DS4 cells was about 39 days, whereas that of those treated with LPS was about 60 days. Chart 4 shows that the effect of LPS was dose dependent. LPS was toxic to SL mice at a dose of 100 μg or less, but it had a lethal effect at 200 μg or more. About 95% of the mice inoculated with 10^5 highly sensitive DS4 cells developed leukemia, even when injected with high doses of LPS. The most striking effect of LPS was seen in mice inoculated with the less sensitive cells. Mice treated with 100 μg of LPS survived for more than 50 days, whereas untreated mice died within 27 days after injection of DS1-1 cells. Since the resistant cells were less sensitive than the sensitive cells to the effect of LPS on induction of differentiation, these *in vivo* results are compatible with *in vitro* findings on inducibility of differentiation of the cells.

The minimum cell numbers of clones DS4, DS1-1, and DR3 required to induce leukemia in syngeneic SL mice on i.p. injection were 3 to 6 × 10⁴, 2 to 5 × 10⁵, and 20 to 50 cells, respectively. The survival time depended on the cell number, and mice inoculated with subthreshold number of the cells...
were followed for 150 days. A longer follow-up is difficult since spontaneous myeloid leukemia frequently develops in aged SL mice (over 1 year). LPS retarded development of leukemia in mice inoculated with $1.5 \times 10^4$ to $1.5 \times 10^6$ DS4 cells (Chart 5). After prolonged LPS treatment of mice inoculated with $1.5 \times 10^4$ cells, the mean survival time was about 73 days, and 4 of 20 mice did not develop leukemia, whereas the mean survival time of untreated mice was about 48 days and all of the mice died of leukemia. Two of 35 mice inoculated with 1 to $1.5 \times 10^5$ cells and treated with LPS did not develop leukemia. However, all of the mice inoculated with $10^6$ cells died of leukemia. These results indicate that LPS significantly prolonged the survival time of mice with the sensitive M1 cells. The survival time of mice with the sensitive cells also prolonged by LPS from S. typhimurium, S. abortus-equi, or E. coli. A single injection of LPS into mice on Day 0 did not affect the survival days, and LPS treatment was effective only when it was started within at least 7 days after inoculation of leukemia cells (Table 1).

**Prolongation of Survival Time by Glucocorticoids.** Since glucocorticoid hormones induce differentiation of M1 cells in vitro (12), we examined their effect on the survival times of mice inoculated with sensitive M1 cells (Table 2). The survival times were prolonged by treatment with dexamethasone, (20 μg/mouse) but they were shortened by a high dose (400 μg/mouse). Similar results were obtained on s.c. injection of prednisolone in corn oil into mice twice a week. These results suggest that, at an optimal dose, glucocorticoid prolongs the survival times of syngeneic SL mice inoculated with sensitive M1 cells.

**Detection of Surface Antigens of Cells by Immune Adherence.** The surface antigens of resistant DR3 cells and sensitive DS4 cells were determined by the immune adherence test against DR3 cells. The immune adherence titers of sensitive cells were similar to those of resistant cells (Chart 6). Antibodies to DR3 cells were completely absorbed with DS4 cells, and the immune adherence reactions were completely negative with normal mouse serum. The surface antigens in sensitive and resistant cells seemed to be qualitatively similar, judging from results of an immune adherence test with antiserum from SL mice immunized with sensitive DS4 cells (data not shown). Therefore, these 2 clone cells, DR3 and DS4, have common antigens and similar surface antigen contents. The other clone, DS1-1, also had a similar surface antigen content.

**Survival Times in Immunodeficient Mice.** When newborn syngeneic SL mice were given i.p. injections of $5 \times 10^5$ cells from cultures of sensitive and resistant M1 cells, mice inoculated with the sensitive DS4 cells survived longer than those given injections of the resistant DR3 cells (Table 3). For confirmation of leukemogenicity in immunodeficient animals, survival of athymic nude BALB/c mice inoculated with the leukemia cells was examined. Results showed that the nude mice with the sensitive cells survived longer than did those with the resistant cells.

---

**Table 1**

<table>
<thead>
<tr>
<th>Treatment of LPSa</th>
<th>Source of LPS</th>
<th>Survival daysb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td>41.8 ± 3.3d</td>
</tr>
<tr>
<td>From Day 14</td>
<td>S. typhimurium</td>
<td>42.8 ± 4.8d</td>
</tr>
<tr>
<td>From Day 7</td>
<td>S. typhimurium</td>
<td>59.7 ± 5.7d</td>
</tr>
<tr>
<td>From Day 0</td>
<td>S. typhimurium</td>
<td>60.4 ± 6.0d</td>
</tr>
<tr>
<td>From Day 0 onlyb</td>
<td>S. typhimurium</td>
<td>41.0 ± 1.4e</td>
</tr>
<tr>
<td>From Day 0</td>
<td>S. abortus-equi</td>
<td>63.8 ± 8.7d</td>
</tr>
<tr>
<td>From Day 0</td>
<td>E. coli</td>
<td>62.0 ± 5.4d</td>
</tr>
</tbody>
</table>

a Mice were given i.p. injections of 25 μLPS starting on the indicated day after inoculation of DS4 cells.
b Each mouse was given an i.p. injection of $10^5$ DS4 cells.
c Mean ± S.D.
d Significantly different from control (p < 0.01).
e Mice were given injections of LPS 3 hr after tumor challenge.

---

**Table 2**

<table>
<thead>
<tr>
<th>Survival daysb</th>
<th>No. of mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>31.5 ± 2.9d</td>
</tr>
<tr>
<td>Treatedc</td>
<td>43.7 ± 4.0d</td>
</tr>
</tbody>
</table>

a Each mouse was given an i.p. injection of $3 \times 10^5$ DS4 cells.
b Mean ± S.D.
c Mice were given i.p. injections of 0.2 ml of PBS containing 20 μg of dexamethasone.
d Significantly different from control (p < 0.01).
Y. Honma et al.

Prolongation of Survival Times of Athymic Nude Mice with M1 Cells by LPS. LPS is reported to be an immunopotentiator in mice and to inhibit growth of some tumors (3, 5, 22, 24–26). Therefore, we examined its effect on the growth of M1 cells in athymic nude mice. Table 4 shows that LPS increased survival times of athymic nude mice inoculated with M1 cells. This finding suggests that the inhibitory effect of LPS is not directly involved in T-lymphocyte-mediated immune responses. The effect of LPS in nude mice seemed to be rather greater than that in normal syngeneic SL mice, possibly due in part to the difference in genetic background of the athymic nude mice.

DISCUSSION

The resistant M1 cell clone used in the present experiments originated from a sensitive M1 cell clone. They showed no detectable differences from the sensitive clone in cell morphology, in vitro proliferation rate, or agglutinabilities with various lectins (11). They also showed no detectable difference from the sensitive clone in tumor-related surface antigens. However, they did differ in survival time in immunodeficient mice. Thus, this difference in survival time does not seem to be due to differences in the immunological properties described above.

Injection of LPS, a potent inducer of differentiation of the cells, greatly prolonged the survival time of mice inoculated with sensitive M1 cells and only slightly prolonged that of resistant cells. This finding is consistent with the effects of LPS on induction of differentiation of sensitive and resistant cells in vivo or in vitro, suggesting that the effect of LPS in stimulating cell differentiation in vivo may be associated with increase in survival time. However, LPS has been shown to have both direct and indirect antitumor effects (3, 5, 22, 24–26, 28). T-lymphocyte-mediated immune responses may not be directly involved in the effect of LPS on the survival time, because LPS also prolonged the survival times of athymic nude mice inoculated with M1 cells. LPS treatment stimulates the antitumor activity of macrophages (7, 8, 26, 30). Moreover, it was recently found that the gene for control of the tumoricidal capacity of macrophages is either closely linked with, or identical to, the LPS-responsive gene (26). Leukocytes are important in production of a differentiation-stimulating factor for M1 cells (15), and one of the many effects of LPS on macrophages is to enhance production of this factor. Therefore, development of cytotoxic macrophages may be associated with increase in production of inducer for differentiation of M1 cells. The inducer also stimulates bone marrow colony formation (6, 9, 27). It has been suggested that the inducer plays a role in the control of granulopoiesis and macrophage production in vivo (21). Butler et al. (5) postulated that one antitumor effect of LPS may be mediated by the bone marrow colony-stimulating factor. Glucocorticoid, which induces differentiation of M1 cells, also prolonged the survival time of mice with sensitive M1 cells, although glucocorticoid is known to be an immunosuppressive agent (18). These results suggest that the effect of LPS on the survival time is partly attributable to its effect in stimulating differentiation of the cells in vivo (Chart 2).

When mice were inoculated with $10^4$ sensitive M1 cells, untreated animals all died of leukemia, but some of those treated with LPS survived. However, LPS treatment alone is not always effective in mice bearing M1 cells and a high dose of LPS had a lethal effect, especially in tumor-bearing animals (4). Dexamethasone, which also induces differentiation, was also effective at a certain dose in increasing the survival times of mice bearing sensitive M1 cells, but a high dose caused considerable side effects, such as immunosuppression. More effective therapy for leukemia with fewer side effects might be achieved by combination therapy with LPS, glucocorticoid, and some other inducers. Alternatively, other inducers with fewer side effects might be more effective in inhibiting the leukemogenicity of M1 cells by inducing their differentiation. Moreover, in order to develop adequate leukemia therapy based on induction of differentiation, we must identify suitable drugs able to induce 100% of the population to differentiate, because if any leukemia cells survive at all, the disease cannot be cured.

Previous studies with Friend erythroleukemia cells indicated that the time course of development of erythroleukemia could be altered by treatment with active differentiation-inducing agents, although none of the compounds tested significantly increased overall survival (20). The previous and the present experiments suggest that cancer therapy might be achieved by inducing phenotypic reversion and normal differentiation of malignant cells. Further experiments on this possibility should contribute to establishment of new forms of cancer therapy.

Table 4

<table>
<thead>
<tr>
<th>Cell clone</th>
<th>No. of cells inoculated/mouse</th>
<th>Survival days</th>
<th>No. of mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn SL mice</td>
<td>DS4 $5 \times 10^4$</td>
<td>32.8 $\pm$ 2.3$^b$</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>DR3 $5 \times 10^4$</td>
<td>22.7 $\pm$ 3.8</td>
<td>9</td>
</tr>
<tr>
<td>Athymic nude mice</td>
<td>DS4 $3 \times 10^4$</td>
<td>51.0 $\pm$ 6.3</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>DR3 $3 \times 10^4$</td>
<td>23.6 $\pm$ 2.1</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>DS4 $10^4$</td>
<td>41.6 $\pm$ 6.1</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>DR3 $10^4$</td>
<td>22.0 $\pm$ 2.0</td>
<td>12</td>
</tr>
</tbody>
</table>

$^a$ All the mice developed leukemia and died.

$^b$ Mean $\pm$ S.D.

Table 5

<table>
<thead>
<tr>
<th>Cell clone</th>
<th>No. of cells inoculated/mouse</th>
<th>Survival days</th>
<th>No. of mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn SL mice</td>
<td>DS4 $5 \times 10^4$</td>
<td>32.8 $\pm$ 2.3$^b$</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>DR3 $5 \times 10^4$</td>
<td>22.7 $\pm$ 3.8</td>
<td>9</td>
</tr>
<tr>
<td>Athymic nude mice</td>
<td>DS4 $3 \times 10^4$</td>
<td>51.0 $\pm$ 6.3</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>DR3 $3 \times 10^4$</td>
<td>23.6 $\pm$ 2.1</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>DS4 $10^4$</td>
<td>41.6 $\pm$ 6.1</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>DR3 $10^4$</td>
<td>22.0 $\pm$ 2.0</td>
<td>12</td>
</tr>
</tbody>
</table>

$^a$ M. Hozumi, unpublished data.
REFERENCES


Prolongation of Survival Time of Mice Inoculated with Myeloid Leukemia Cells by Inducers of Normal Differentiation

Yoshio Honma, Takashi Kasukabe, Junko Okabe, et al.


Updated version  Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/39/8/3167

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.